Phenothiazines in treatment of HIV infection: (A review)

Acta Microbiologica et Immunologica Hungarica

Volumn 50, Issue 1, 2003, Pages 43-53

  Aszalos, A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Phenothiazines; Treatment of HIV infections

Indexed keywords

1 (2 CHLOROETHYL) 3 (2 CHLORO) 10H PHENOTHIAZIN 10 YLBUTYL 1 UREA; 10 (3 PHTHALIMIDO)PROPYL 2 CHLORO 10H PHENOTHIAZINE; 7,8 DIHYDROXYCHLORPROMAZINE; 7,8 DIOXOCHLORPROMAZINE; CHLORPROMAZINE; CLOMIPRAMINE; DOXEPIN; IMIPRAMINE; MAPROTILINE; PERPHENAZINE; PHENOTHIAZINE DERIVATIVE; PROTRIPTYLINE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHIBITION KINETICS; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; CELL LINE; CHEMISTRY; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS;

ANTI-HIV AGENTS; CELL LINE; HIV INFECTIONS; HIV-1; HUMANS; PHENOTHIAZINES; VIRUS REPLICATION;

EID: 0038578091     PISSN: 12178950     EISSN: None     Source Type: Journal    
DOI: 10.1556/AMicr.50.2003.1.5     Document Type: Review

References (31)

1. Wampler G: The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis. Drugs, 25, 35-51, 1983
2. Motohashi N, Kurihara T, Kawase M, Hever A, Tanaka M, Szabo D, Nacsa J, Yamanaka W, Kerim A and Molnar J: Drug resistance reversal, anti-mutagenicity and antiretroviral effect of phtalimudo- and chloroethyl-phenothiazines. Anticancer Res., 17, 3537-1544, 1997
3. Motohashi N, Sakagami H, Kurihara T, Csuri K and Molnar J: Antiplasmid activity of phenothiazines, benzo[a]phenothiazines and benz[c]acridines. Anticancer Res., 12, 135-139, 1992
4. Hewlett I, Lee S, Molnar J, Foldeak S, Pine PS, Weaver JL and Aszalos A: Inhibition of HIV infection of H9 cells by chlorpromazine derivatives. J Acquired Immune Deficiency Syndromes Human Retrovirology, 15, 16-20, 1997
5. Petracek FJ, Bier JH, Bopp B and Mitchell B: Chemistry and structure activity relationships of psychotropic drugs. In: Clarke WG and del Guidice J. (Eds) Principles of Psychopharmacology, Academic, New York, 1978
6. Plosker GL and Noble S: Indinavir: a review of its use in the management of HIV infection. Drugs, 58, 1165-1203, 1999
7. Weaver JL, Gergely P, Pine PS, Patzer E and Aszalos A: Polyonic compounds selectively alter availability of CD4 receptor for HIV coat protein rgp120. Aids Res. Hum. Retroviruses, 6, 1125-113, 1990
8. Jonak ZL, Clark RK, Matour D, Trulli S, Craig R, Henri E, Lee EV, Greig R and Debouch Ch: A human lymphoid recombinant cell line with functional human immunodeficiency virus type 1 envelope. Aids Res. Hum. Retroviruses, 9, 23-32, 1993
9. Dhawan S, Heredia A, Lai RB, Leyda LM, Epstein JS and Hewlett IK: Interferon-gamma induces resistance in primary monocytes against human immunodeficiency virus type-1 infection. Biochem. Biophys. Res. Commun., 201, 756-761, 1994
10. Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykans J, Schellekens K, Janssen MAC, De Clercq E and Janssen PAJ: Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature, 343, 470-474, 1990
11. Lialiaris Th, Pantazaki A, Sivridis E and Mourelatos D: Chlorpromazine-induced damage on nucleic acids: a combined cytogenic and biochemical study. Mutation Res., 265, 155-163, 1992
12. Glocke E: Review of the genotoxic properties of chlorpromazine and related phenothiazines. Mutation res., 366, 9-21, 1996
13. Molnar J: The role of charge distribution of tricyclic compounds in antibacterial, antiviral and antiplasmid effects. In: N Keyser, F Gutman, G Eckert (Eds) Electropharmacology, CRC Press, 1090, pp 205-219
14. Szekely Z, Fabian P, Torday LL, Michejda CJ and Aszalos A: Binding between the CD4 receptor and polysulfonated azo-dyes. An exploratory theoretical study on action-mechanism. Theochem., 423, 153-159, 1998
15. Nacsa J, Nagy L, Molnar J and Molnar J: Trifluoperazine and its metal complexes inhibit the maloney leukemia virus reverse transcriptase. Anticancer Res., 12, 135-139, 1992
16. Motohashi N, Kawase M, Kurihara T, Hever A, Nagy Sz, Ocsovszki I, Tanaka M and Molnar J: Synthesis and antitumor activity of 1-(2-chloroethyl)-3-(2- substituted-1-H-phenothiazine-10-yl)alky-1-ureas as potent anticancer agent. Anticancer Res., 16, 2525-2531, 1996
17. Kidd SE, Nelson MJ, Epstein M, Aszalos A, Pine S and Molnar J: Inhibition of GP120 and antibodies binding to CD4 by metal complexes of promazines. Antiinfective Drugs and Chemotherapy, 15, 71-77, 1997
18. Weaver JL, Pine PS, Anand R, Bell S and Aszalos A: Inhibition of the binding of HIV rgp120 to CD4 by dyes. Antiviral Chemistry Chemother., 3, 147-151, 1992
19. Brennan TM, Taylor DL, Bridges CG, Leyda JP and Tyms AS: The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. Antiviral Res., 26, 173-187, 1995
20. Kilby JM, Hopkins S, Venetta TM, Dimassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Hohnson MR, Nowak MA, Shaw GM and Saag MS: Potent suppression of HTV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med., 4, 1302-1307, 1998
21. Arenzana-Selsdelos F, Virellzier JL, Rousset D, Clark-Lewis I, Loetscher P, Moser B and Bagglolini M: HIV blocked by chemokine antagonist. Nature, 383, 400, 1996
22. Feng Y, Broder CC, Kennedy PE and Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science, 272, 872-876, 1996
23. Szabo D, Szabo GJr, Ocsovszki I, Aszalos A and Molnar J: Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo. Cancer Lett., 139, 115-119, 1999
24. Ganapathi R, Kuo T, Teeter L, Grabowski D and Ford J: Relationship between expression of P-glycoprotein and efficacy of trifuoperazine in multidrug-resistant cells. Molec. Pharmacol., 39, 1-8, 1991
25. Lee CGL, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I and Dey S: HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry, 37, 3594-3601, 1998
26. Klimecki WT, Futscher BW, Grogan TM and Dalton WS: P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood, 83, 2451-2458, 1994
27. Ayuso JL: Use of psychotropic drugs in patients with HIV infection. Drugs, 47, 599-610, 1994
28. Ibrahim S, Peggins J, Knapton A, Licht T and Aszalos A: Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesies, diuretics, and quinolon antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation. Anticancer Res., 21, 847-856, 2001
29. Preston SL, Postelnick M, Purdy BD, Petrolati J, Aasi H and Stein DS: Drug interactions in HIV-positive patients initiated on protease inhibitor therapy. AIDS, 12, 228-230, 1998
30. Elliott AJ, Uldall KK, Bergam K, Russo J, Claypool K and Roy-Byrne PP: Randomized, placebo-controled trial of paroxetine versus imipramin in depressed HIV-positive outpatients. Am. J. Psychiatry, 155, 367-372, 1998
31. Moltke LL, Greenblatt DJ, Duan SX, Daily JP, Harmatz JS and Shader RI: Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J. Pharm. Sci., 87, 1184-1189, 1998